Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, with virtually all living cells utilize exosome-mediated communication. Today, exosomes are being explored across a diverse range of therapeutic and diagnostic applications, with particular attention being given by the pharmaceutical industry to drug-loaded exosomes. [Read more…]
The Rise of Exosome-Based Cosmeceuticals in 2026
A cosmeceutical is defined as a product that is marketed as a cosmetic but has the capacity to exert pharmaceutical effects. In recent years, exosomes have been utilized within the global cosmetics industry to manufacture and market skincare products that use the power of these small extracellular vesicles to enhance a broad range of traits, including but not limited to skin health and rejuvenation, scar improvement, hair regrowth, anti-aging effects, and beyond. Exosomes can provide bioactive substances such as proteins, lipids, and nucleic acids to the target cells to alter gene expression and cellular function. Importantly, exosomes can also induce collagen formation, enhance tissue regeneration, and exert anti-inflammatory properties. [Read more…]
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF
SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA.
Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioactive material fields. [Read more…]
Exploring Advanced Therapies in Diabetes Treatment: A Glimpse into the Future
Diabetes is a chronic condition affecting millions globally, characterized by high blood sugar levels due to the body’s inability to produce or effectively use insulin. Traditional management strategies, including lifestyle modifications and medications, have been vital in controlling diabetes, but they often fall short of addressing the disease’s complexities and long-term complications. In recent years, advanced therapies have emerged, offering new hope for patients.
These therapies encompass innovations such as regenerative medicine, advanced insulin delivery systems, and gene editing technologies, each bringing us closer to more effective and personalized treatments. [Read more…]
Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production
September 24, 2025 – Takara Bio Europe announces the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs).
MSC-derived EVs are increasingly recognized as next-generation, cell-free therapeutic candidates, offering regenerative and immunomodulatory benefits without the safety concerns associated with administering intact MSCs. As the field shifts from MSC-based approaches to MSC-EVs, researchers are seeking solutions that deliver both robust yields and reproducible quality at scale. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 27
- Next Page »